Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 1999

View Archived Issues

Amarillo's fibromyalgia trial expanded

Natural insulin-sensitizing agent may help cure PCOS infertility

Oxigene: Annual Report 1998/Q1 1999 highlights

Company Profile: Nanosyn

Sublingual apomorphine aids in erectile dysfunction

Lilly: Annual Report 1998

Neurocrine Biosciences: Q1 1999 highlights

Yamanouchi describes novel series of factor Xa inhibitors

IND exemption granted to Polydex's STD/contraceptive drug

Potent, orally active antiulcer agents synthesized at SS Pharm.

Sankyo's new antibiotics described in patent literature

New antiinflammatory/analgesic agents with both topical and oral activity

Telmisartan now available in Spanish pharmacies

Naturally occurring terpene with immunosuppressive and neovascularization-inhibitory effects

NA-00226B and C, produced by Streptomyces, inhibit cAMP PDE activity

Licensing opportunity from NIH: recombinant antitumor RNases

HCV antisense oligonucleotide reduces HCV gene expression in mouse model

Progenics: Q1 1999 highlights

Licensing opportunity from NIH: BChE inhibitors for Alzheimer's disease Rx, Dx

Phase I trial results reported for GA-EPO at nephrology congress

AVI BioPharma: Q1 1999 highlights

KH-1060: immunomodulating effects studied in mouse skin graft model

LU-135252 used to investigate role of ETA receptor in cardiac hypertrophy

Beneficial effects of TAK-044 in kidney autotransplanted dogs

PST-2238: novel antihypertensive agent targeting ouabain

Structural Bioinformatics develops antagonists of BcL-2 gene product

Flixotide submitted for COPD in major markets

Single-isomer valproic acid patented in Japan